

## Henry Schein Affiliate to Resume Shipment of Anesthetic Product

September 23, 1999

Business/Medical Editors

MELVILLE, N.Y.--(BUSINESS WIRE)--Sept. 23, 1999--Henry Schein, Inc. (Nasdaq: HSIC) announced today that Novocol Pharmaceutical of Canada, Inc., (Novocol), an affiliated company in which it owns a non-controlling interest, has been notified by the United States Food and Drug Administration (FDA) that Novocol is free to resume production of its dental anesthetic products for shipment into the United States. The Canadian Health Protection Branch (HPB) has provided Novocol with a similar notification for production and shipment into Canada.

In anticipation of this result, Novocol has already resumed limited production. Novocol has advised that it will ramp up production over the next few quarters and will, during this time period, explore opportunities to increase its capacity to historical levels. Novocol has further advised that it expects to resume shipment of its products to the United States early in the fourth quarter of 1999.

Earlier this year, Novocol, in cooperation with the FDA, voluntarily recalled certain batches of its anesthetic products and suspended shipping these products to the United States pending a review of all protocol and policies regarding the manufacturing of the anesthetic products.

Henry Schein's equity in earnings of this unconsolidated affiliate was \$1.6 million for 1998. In addition, these products represented \$15 million of Henry Schein's 1998 sales.

Henry Schein, Inc. is the largest distributor of healthcare products and services to office-based healthcare practitioners, including dental practices and laboratories, physician practices and veterinary clinics. The Company, recognized for its excellent customer service and low prices, serves more than 300,000 customers worldwide. Headquartered in Melville, New York, the Company employs over 6,000 people in 16 countries. Sales in 1998 were \$1.9 billion. For more information, visit the Henry Schein website at <http://www.henryschein.com>.

Certain information contained herein includes information that is forward-looking. The matters referred to in forward-looking statements may be affected by the risks and uncertainties involved in the Company's business. These forward-looking statements are qualified in their entirety by the cautionary statements contained in the Company's Securities and Exchange Commission filings.

--30--es/ny\*

CONTACT: Henry Schein, Inc.  
Steven Paladino  
Senior Vice President and Chief Financial Officer  
516/843-5500  
or  
Susan Vassallo  
Manager, Investor and Public Relations  
516/843-5562  
[svassa@henryschein.com](mailto:svassa@henryschein.com)

KEYWORD: NEW YORK

INDUSTRY KEYWORD: MEDICINE BIOTECHNOLOGY